Standard BioTools vs Wave Life Sciences
LAB and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LAB and WVE compare
Wave Life Sciences is the larger company, worth 2.7 times as much as Standard BioTools ($675M against $252M).
Standard BioTools keeps more of each dollar of sales as profit, with a net margin of 100% compared with −297% at Wave Life Sciences.
Standard BioTools scores higher on the StockData Score (12 against 10 for Wave Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LAB | WVE |
|---|---|---|
| Size and price | ||
| Market cap | $252M | $675M |
| Share price | $0.643 | $3.42 |
| Change, 1 year | −45.0% | −51.5% |
| Change, 5 years | −85.7% | −20.6% |
| Beta (5Y) | 1.53 | 1.32 |
| Employees | 389 | 317 |
| StockData Score | ||
| Total score | 12 (better) | 10 |
| Valuation score | 4 (better) | 3 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 2.9× | – |
| P/S | 3.0× (better) | 9.5× |
| P/B | 0.5× (better) | 1.7× |
| FCF yield | −32.7% | −30.9% (better) |
| Fair value | $4.90 | $5.31 |
| Margin of safety | 86.9% (better) | 35.6% |
| Growth | ||
| Revenue growth (TTM) | −4.8% | – |
| Revenue growth, 5Y average | −9.2% | 16.3% (better) |
| Profitability | ||
| Gross margin | 50.5% | – |
| Operating margin | −113% (better) | −321% |
| Net margin | 100% (better) | −297% |
| FCF margin | −97.6% (better) | −294% |
| Return on equity | 17.6% (better) | −80.0% |
| Return on invested capital | −60.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.10 (better) | 8.38 |
| Altman Z-score | −0.34 (better) | −0.66 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 75.4% | 92.6% |
| Held by insiders | 70.2% | 23.1% |
| Insider net buying, 12 months | $550K | $66.5M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 1.9% | 13.6% |
Go deeper
- LAB stock overview
- LAB income statement
- LAB valuation and score
- WVE stock overview
- WVE income statement
- WVE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.